-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV,...
More »SEARCH RESULT
Total Matching Records found : 144
Four states in south make up 50% of HIV cases -Adarsh Jain
-The Times of India COIMBATORE: Tamil Nadu, Andhra Pradesh, Telangana and Karnataka account for 3.6 lakh HIV cases, about 50% of the patients in the country. The southern states are also among the top four in the country, with Tamil Nadu alone having 80,685 HIV affected people of the total 7.7 lakh as on May 2014. Andhra Pradesh (including Telengana) tops the list with 1.7 lakh HIV affected people, followed by Maharashtra...
More »What is novelty? -Rajshree Chandra
-The Indian Express The era of globalised markets is also an era of globalised sovereignties. Nation states must constantly sync their policies with global constituencies of policies and citizens. At times, domestic disharmony is the price nation states may be required and willing to pay. The case in point here is the proposed review of the intellectual property rights (IPR) policy, particularly those clauses that are related to pharmaceutical patent policy....
More »24% of global missed TB cases in India: WHO -Kounteya Sinha
-The Times of India LONDON: One in every four missed cases of tuberculosis (TB) globally is in India.The World Health Organisation has found that India tops the list of the world's missed TB cases. Almost 24% of the world's missed TB cases are from India, according to the Global TB Report 2014 released on Thursday. Ten countries accounted for 74% (2.4 million) of the estimated "missed" cases globally in 2013. The number of...
More »Mala Fide Decision on Drug Prices
-Economic and Political Weekly The decision to reduce the powers of the drug pricing body goes against the interest of public health. The decision of the Government of India to withdraw the power of the National Pharmaceutical Pricing Authority (NPPA) to set price controls on drugs that are not on the National List of Essential Medicines (NLEM) raises questions on the Narendra Modi regime's commitment to people's welfare. One must ask if...
More »
